Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Hyperparathyroidism primary
ADR ID BADD_A02135
ADR Hierarchy
05      Endocrine disorders
05.04      Parathyroid gland disorders
05.04.01      Hyperparathyroid disorders
05.04.01.005      Hyperparathyroidism primary
14      Metabolism and nutrition disorders
14.04      Bone, calcium, magnesium and phosphorus metabolism disorders
14.04.01      Calcium metabolism disorders
14.04.01.021      Hyperparathyroidism primary
Description A condition of abnormally elevated output of PARATHYROID HORMONE due to parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. It is characterized by the combination of HYPERCALCEMIA, phosphaturia, elevated renal 1,25-DIHYDROXYVITAMIN D3 synthesis, and increased BONE RESORPTION. [MeSH]
MedDRA Code 10020707
MeSH ID D049950
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Hyperparathyroidism primary | Primary hyperparathyroidism | Hyperparathyroidism, Primary | Hyperparathyroidisms, Primary | Primary Hyperparathyroidisms | Primary Hyperparathyroidism
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00066Alendronic acid0.000132%
BADD_D00142Anastrozole0.000477%
BADD_D00337Calcitriol0.000447%
BADD_D00469Cinacalcet hydrochloride--
BADD_D00979Furosemide0.000056%
BADD_D01083Hydrochlorothiazide0.000010%
BADD_D01303Lithium carbonate0.002409%
BADD_D01304Lithium cation0.000288%
BADD_D02392Zoledronic acid--
BADD_D02412Octreotide--
BADD_D02434Cinacalcet0.000782%
The 1th Page    1    Total 1 Pages